A study with the APP/PS1 transgenic mice model of AD indicated higher TMAO-levels in plasma to be associated with cognitive and pathological deterioration, while treatment with the TMA formation inhibitor 3,3-Dimethyl-1-butanol (DMB) alleviated cognitive deterioration and defective synaptic plasticity [191]. The gene discussed is APP; the disease is Alzheimer disease.